What you should know:
- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous blood glucose monitoring for people with diabetes, today announced that the FDA has cleared Dexcom’s Stelo – the first glucose biosensor that does not require ‘prescription.
- Approximately 25 million people in the United States have type 2 diabetes, do not use insulin, and can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available to them by prescription. Stelo, authorized for use without a prescription, will allow this population even easier access to cutting-edge CGM technology and provide an option for those who do not have insurance coverage for CGM.
Introducing the first over-the-counter glucose biosensor that does not require a prescription
Continuous glucose monitoring plays a vital role in the management of type 2 diabetes and has proven benefits when used alone or in combination with other diabetes and weight management medications.8 Studies show that the use of Dexcom continuous glucose monitoring by people with type 2 diabetes is associated with clinically meaningful improvement in on-time, HbA1c, and quality of life.
“Dexcom continues to lead innovation in the CGM market, with a long list of first-to-market advancements. Dexcom was the first to connect CGM to multiple insulin delivery devices, the first to connect CGM to a smartphone, the first to replace needles‡ for treatment decisions, and is now creating a new category by offering the first glucose biosensor cleared for over-the-counter use,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Based on our experience serving people with type 2 diabetes not using insulin, we developed Stelo with their unique needs in mind. »
